Ardent Health Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
11.9% vs price
Base Case (Median)
90.6% vs price
Bull Case (75th pct.)
210.5% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-14.99 | -237.6% | High (40%) |
| PE Comparable | $12.24 | 12.4% | Medium (25%) |
| Graham Number | $12.18 | 11.8% | Medium (40%) |
| EV/EBITDA | $35.33 | 224.4% | Medium (20%) |
| EV/FCF | $42.71 | 292.2% | Medium (20%) |
| Earnings Power Value | $29.28 | 168.8% | Medium (50%) |
Based on 6 out of 8 methods, ARDT appears undervalued at the current price of $10.89. The base case fair value of $20.76 implies 90.6% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.